#United States #AbbVie #North Chicago #Upadacitinib #Vitiligo

AbbVie Gains EU Approval for Upadacitinib

AbbVie has made significant strides in dermatological therapies with its recent announcement that the European Commission has granted approval for Upadacitinib as a treatment for adults and adolescents aged 12 and over who suffer from non-segmental vitiligo (NSV). This marks a pivotal moment as Upadacitinib becomes the first and only systemic therapy approved in the European Union specifically targeting this chronic autoimmune skin condition.

The approval is based on the promising results from the Phase 3 clinical trial program, named Viti-Up, which evaluated the efficacy and safety of Upadacitinib in NSV patients. Notably, data demonstrated that patients receiving Upadacitinib achieved statistically significant improvements in skin repigmentation, when compared to a placebo group at the 48-week mark. The trial results indicated that a notable percentage of participants reached the primary endpoints, T-VASI 50 for overall body repigmentation and F-VASI 75 for facial repigmentation.

In a statement about this approval, Dr. Roopal Thakkar, AbbVie’s Executive Vice President of Research and Development, emphasized the importance of this treatment option for those living with chronic autoimmune diseases like vitiligo. He noted the limited treatment alternatives currently available for vitiligo patients, highlighting Upadacitinib's critical role in addressing these unmet medical needs across Europe.

Vitiligo emerges when melanocytes, the cells responsible for skin pigmentation, are selectively destroyed. This leads to irregular white patches on the skin, which can significantly affect patients not just cosmetically, but also psychologically, often resulting in heightened anxiety and depression. Non-segmental vitiligo represents the most prevalent type of vitiligo, accounting for approximately 84% of cases. Thus, the introduction of Upadacitinib as a therapeutic option is a significant advancement in managing this challenging condition.

Data Supporting Approval

The European Commission's approval was substantiated by data from the Phase 3 Viti-Up clinical trial (M19-044). This comprehensive program encompassed two randomized, placebo-controlled, double-blind studies that evaluated the efficacy, safety, and tolerability of Upadacitinib among eligible patients. In these studies, participants were randomly assigned to receive either 15 mg of Upadacitinib or a placebo, continuing their treatment for 48 weeks.

Results indicated that the 15 mg Upadacitinib group achieved the primary endpoints of significant and clinically meaningful improvements in both T-VASI and F-VASI assessments, compared to the placebo group. These results not only validated the treatment’s effectiveness but also highlighted its safety profile, which remained consistent with known data for other approved indications of Upadacitinib, with no new safety signals identified during the trial.

Dr. Diamant Thaçi, professor at the University of Lübeck and principal investigator of the Viti-Up study, noted, "The approval of Upadacitinib offers an advanced systemic treatment option that targets the immune dysfunction underlying vitiligo. This comprehensive approach to disease management is essential in providing better care for patients suffering from this unpredictable autoimmune condition."

Besides NSV, Upadacitinib is already approved within the EU for treating several other conditions, including atopic dermatitis, rheumatoid arthritis, and ulcerative colitis, adding to its versatility in addressing various autoimmune and inflammatory disorders.

Overview of the Viti-Up Clinical Trial

The Viti-Up program was designed to rigorously assess Upadacitinib among adults and adolescents diagnosed with NSV. Spanning a total treatment period of 160 weeks, the trial was conducted at over 90 sites globally, with 614 patients being randomized for analysis. The primary efficacy endpoints focused on the percentage of patients achieving significant repigmentation at the 48-week mark, underscoring Upadacitinib’s potential impact in improving life quality for affected individuals.

As a selective and reversible JAK inhibitor, Upadacitinib represents a promising advancement in the treatment landscape of autoimmune diseases, with ongoing research exploring its use in conditions such as hidradenitis suppurativa and systemic lupus erythematosus.

Conclusion

AbbVie continues its commitment to transforming treatment paradigms for autoimmune and inflammatory diseases. The approval of Upadacitinib for NSV is a testament to their dedication to innovation and addressing patient needs. As the healthcare landscape evolves, AbbVie remains focused on creating solutions that improve lives across various therapeutic areas. For more information, visit AbbVie’s Immunology website.